🇺🇸 FDA
Pipeline program

Praluent

R727-CL-1609

Approved small_molecule terminated

Quick answer

Praluent for Heterozygous Familial Hypercholesterolemia is a Approved program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Heterozygous Familial Hypercholesterolemia
Phase
Approved
Modality
small_molecule
Status
terminated

Clinical trials